Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research • 05/09/24
Recursion Provides Business Updates and Reports First Quarter 2024 Financial ResultsGlobeNewsWire • 05/09/24
Recursion Pharmaceuticals (RXRX) Increases Yet Falls Behind Market: What Investors Need to KnowZacks Investment Research • 05/03/24
Recursion Pharmaceuticals, Inc. (RXRX) is Attracting Investor Attention: Here is What You Should KnowZacks Investment Research • 05/02/24
Recursion to Report First Quarter 2024 Business Updates and Financial Results on May 9GlobeNewsWire • 05/02/24
Nvidia Owns a 3.4% Stake in This Innovative Artificial Intelligence (AI) Stock Cathie Wood LovesThe Motley Fool • 04/27/24
Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial OfficerGlobeNewsWire • 04/16/24
Wall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for April 2024InvestorPlace • 04/15/24
Can Recursion Pharmaceuticals Stock Double in 5 Years? Here's What It Would Take.The Motley Fool • 04/10/24
Down -26.36% in 4 Weeks, Here's Why Recursion Pharmaceuticals (RXRX) Looks Ripe for a TurnaroundZacks Investment Research • 04/03/24
All You Need to Know About Recursion Pharmaceuticals (RXRX) Rating Upgrade to BuyZacks Investment Research • 04/01/24
Recursion Pharmaceuticals Stock Has 33% Upside, According to 1 Wall Street AnalystThe Motley Fool • 03/07/24
Recursion Hosts Second Annual Rare Disease Day Events for Utah's Rare Disease CommunityGlobeNewsWire • 03/01/24